CD47 blocking agents, including anti-CD47 antibody, anti-SIRPα antibody, and SIRPα-Fc fusion protein, have demonstrated significant efficacy in suppressing the proliferation of diverse tumor types, encompassing colon cancer, breast cancer, pancreatic neuroendocrine tumors, ovarian cancer, leiomyosarcoma, glioblastoma, and small-cell lung cancer [6, 13, 43–45]. Here, SIRPA is linked to breast carcinoma.